-
IRBs often struggle with determining risks of social and behavioral research studies. Its easy to be both too cautious and too complacent.
-
There are no industry standards for handling incidental findings (IFs) in research.
-
As technology in genetic and genomic research expands, most if not all IRBs will face the issue of incidental findings, including how to manage them, and whether researchers have a duty to report them to study participants, experts say.
-
The Cincinnati Childrens Hospital Medical Center IRB and a special task force developed guidance and a template for improving and simplifying informed consent forms.
-
The exponential increase in smartphones and social networking sites has led to concerns from some patients regarding the possible unlawful distribution of images outside the realms of their care.
-
An IRB member and human research protection expert learned firsthand how complicated informed consent (IC) forms could be when her granddaughter was seriously ill.
-
While the informational quality of internationally registered trials has increased, theres still room for improvement, according to a recent study.
-
One chief hurdle in human research protection program (HRPP) accreditation is the mindset that its all about the IRB, an expert says.
-
The IRB at Grand Valley State University in Allendale, MI, uses a matrix that clarifies how IRB members and staff might describe various potential harms at four levels, from no more than minimal risk to high risk.
-
Technology advances have driven increased interest in molecular studies involving tissue analyses. As a result, biotech firms increasingly are asking scientists to sell human tissues for study by outside enterprises.
